Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially ...
Think Stealth When Moving Defence Building. To band or life partner? Our origin is wrong. This policeman is probably crate and post content. These optimization criteria can help m ...
Morning Overview on MSN
Researchers test slow-release drugs and implants to regrow arthritic joints
A growing cluster of laboratory and early clinical studies is testing whether injectable hydrogels, slow-release drug depots, ...
Injections against hay fever were stopped after safety fears. But Lydia Spencer-Elliott discovers there’s a safer treatment ...
ARCALYST is the first-and-only FDA approved therapy for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is a weekly, ...
MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha(R) (evolocumab injection) for eligible ...
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...
CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha® (evolocumab injection) ...
Priorities for the Newly Elected Government in the Short to Medium Term” was held on March 4, 2026, at the BRAC Center, Dhaka ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results